Solid Biosciences Inc.

SLDB | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.87

+$0.33 (+3.86%)

Sep 22, 2026, 11:07 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.86%

(1D)

Rating

Updated: Aug 15, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $873.25M

1D Range

8.60 8.92

52W Range

3.79 11.45

Valuation (TTM)

PE -4.47

PB 2.25

EV/EBITDA -2.36

Valuation (NTM)

Forward PE N/A

Forward PEG 2.76

Price Target $20.50

Cash Flow

FCF Yield -28.0%

SBC Adj. FCF Yield -31.1%

SBC Impact -11.2%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -100.0%

Dil EPS 3Y | 5Y 21.8% | 45.5%

FCF 3Y | 5Y -50.2% | -24.2%

Returns

ROA -49.2%

ROE -72.3%

ROIC -53.8%

Financial Health

Net Cash

$357.52M

Current Ratio 13.82

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene tran...

Sector Healthcare

Industry Biotechnology

Employees 121

IPO Date Jan 25, 2018

Website www.solidbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$19

Upside

+114.21%

Buy (10)

Hold (0)

Sell (0)

Analyst Details ➞